Table 1 |
|||||||
|
Combined relative risks for breast cancer associated with different classifications of mammographic density, study designs, and study populations from meta-analysis [3] |
|||||||
| General population |
Symptomatic population |
||||||
|
|
|
||||||
| Incidence studies |
Prevalence studies |
||||||
|
|
|
||||||
| Classification |
Cases/Non-casesa |
RR (95% CI) |
Cases/Non-casesa |
RR (95% CI) |
Cases/Non-casesa |
RR (95% CI) |
|
|
|
|||||||
| Wolfe parenchymal pattern |
2,664/23,469b |
2,169/32,184b |
1,857/25,394b |
||||
| N1 |
181/3,613 |
1.0 |
557/15,731 |
1.0 |
428/3,318 |
1.0 |
|
| P1 |
525/6,682 |
1.8 (1.4, 2.2) |
519/9,684 |
1.3 (1.0, 1.5) |
315/5,031 |
1.0 (0.77, 1.3) |
|
| P2 |
1,162/10,433 |
3.1 (2.5, 3.7) |
660/4,369 |
2.0 (1.3, 3.0) |
526/5,128 |
1.5 (0.91, 2.4) |
|
| DY |
246/2,309 |
4.0 (2.5, 6.3) |
294/2,216 |
2.4 (2.0, 3.0) |
400/4,976 |
1.7 (1.0, 2.8) |
|
| Percentage mammographic density |
4,508/8,342b |
2,219/4,063b |
160/160b |
||||
| <5% |
1,194/1,744c |
1.0 |
643/1,182c |
1.0 |
35/84c |
1.0 |
|
| 5%–24% |
1.8 (1.5, 2.2) |
1.4 (1.1, 1.8) |
|||||
| 25%–49% |
1,049/1,045 |
2.1 (1.7, 2.6) |
589/835 |
2.2 (1.8, 2.8) |
66/35 |
5.5 (2.8–11) |
|
| 50%–74% |
2.9 (2.5, 3.4) |
438/665 |
2.9 (2.3, 3.8) |
34/23 |
4.8 (2.2–11) |
||
| 75%+ |
1,211/999 |
4.6 (3.6, 5.9) |
190/282 |
3.7 (2.7, 5.0) |
25/18 |
4.3 (1.8–10) |
|
| BI-RADS |
1,992/104,663b |
Vacekand Geller [30] |
Ziv et al. [57] |
397/1,589b |
|||
| Fatty |
62/7,550 |
1.0 (Ref) |
0.3 (0.2, 0.4) |
20/134 |
1.0 |
||
| Scattered density |
950/52,379 |
2.2 (1.6, 3.0) |
1.0 (Ref) |
216/957 |
1.6 (0.9, 2.8) |
||
| Heterogeneous density |
783/36,564 |
3.0 (2.2, 4.1) |
1.3 (1.1, 1.5) |
117/407 |
2.3 (1.3, 4.3) |
||
| Extremely dense |
197/8,170 |
4.0 (2.8, 5.7) |
20.1 (1.6, 2.8) |
44/91 |
4.5 (1.9, 10.6) |
||
|
|
|||||||
|
aCases and controls from individual categories may not add to the overall number of cases and controls used in the meta-analysis since categories from individual studies did not always coincide with those presented in the meta-analysis. Only numbers of cases and controls from studies with these categories are presented and used for the calculation of prevalence. bTotal cases and noncases used in meta-analysis by McCormack and colleagues [3] for each classification and study type. cWhen possible, categories were combined to provide the maximum contribution of cases and controls from individual studies. BI-RADS, Breast Imaging Reporting and Data System; CI, confidence interval; Ref, reference; RR, relative risk. |
|||||||
|
Vachon et al. Breast Cancer Research 2007 9:217 doi:10.1186/bcr1829 |
|||||||